Evicenter
P&T meetings

Lirafugratinib (Lyrfigtu)

Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma

Also known as RLY-4008
Regulatory submission
NDA submitted January 2026
Last updated
158 sources

Product information and disease descriptionProduct descriptionProduct informationDosing and administration

Administration

3 evidence topics · 1 source

Route, food, and swallowing

“Take LYRFIGTU with or without food [see Clinical Pharmacology (12.3)].” (opens the prescribing information at this quote)

“Swallow capsules whole. Do not open, break or chew the capsules.” (opens the prescribing information at this quote)

Missed doses and vomiting

“If a dose of LYRFIGTU is missed, take the missed dose as soon as possible within 4 hours. If a dose is missed by 4 hours or more, skip the missed dose and take the dose at the next scheduled time.” (opens the prescribing information at this quote)

“If vomiting occurs after taking LYRFIGTU, do not take another dose. Take LYRFIGTU at the next scheduled time.” (opens the prescribing information at this quote)

Patient counseling on phototoxicity

“Inform patients that LYRFIGTU may cause phototoxicity and advise the use of sunscreen, protective clothing, and sunglasses, as well as minimizing sun exposure [see Nonclinical Toxicology (13.2)].” (opens the prescribing information at this quote)